Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03104439 · ClinicalTrials.gov registry record · Phase 2
Nivolumab and Ipilimumab and Radiation Therapy in MSS and MSI High Colorectal and Pancreatic Cancer
A Phase 2 study of Pancreatic Cancer and Microsatellite Stable Colorectal Cancer, sponsored by Massachusetts General Hospital.
- Active
- Registry status
- Phase 2
- Development phase
- 84
- Enrollment target
- 1
- Study location
NCT03104439 is a Phase 2 study of Pancreatic Cancer and Microsatellite Stable Colorectal Cancer that is active but no longer recruiting, run by Massachusetts General Hospital. The registered enrollment target is 84 participants, below the 393-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (79% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03104439, a Phase 2 study of Pancreatic Cancer and Microsatellite Stable Colorectal Cancer, is active but no longer recruiting, sponsored by Massachusetts General Hospital.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 84 participants
- Enrollment target
- 1
- Study location
Study Summary
This research study is studying a combination of drugs with radiation therapy as a possible treatment for Microsatellite Stable Colorectal Cancer, Pancreatic Cancer, or MSI High Colorectal Cancer. The interventions involved in this study are: * Nivolumab * Ipilimumab * Radiation Therapy
Conditions Studied
Interventions
- DRUG Nivolumab
- DRUG Ipilimumab
- RADIATION Radiation Therapy
Study Locations (1)
Massachusetts
- Massachusetts General Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 84 participants |
| Start Date | 2017-05-10 |
| Est. Completion | 2027-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03104439
The ClinicalTrials.gov registry entry for NCT03104439 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 84 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 393-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (79% lower). The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Pancreatic Cancer appearing as the primary indexed condition, and to 3 interventions - of which Nivolumab is the first listed.
NCT03104439 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT03104439 about?
NCT03104439 is a clinical study titled "Nivolumab and Ipilimumab and Radiation Therapy in MSS and MSI High Colorectal and Pancreatic Cancer". This research study is studying a combination of drugs with radiation therapy as a possible treatment for Microsatellite Stable Colorectal Cancer, Pancreatic Cancer, or MSI High Colorectal Cancer. The interventions involved in this study are: * Nivolumab * Ipilimumab * Radiation Therapy
What is the current status of trial NCT03104439?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 84 participants. The study started on 2017-05-10. Estimated completion is 2027-04.
What conditions does trial NCT03104439 study?
This clinical trial studies the following conditions: Pancreatic Cancer, Microsatellite Stable Colorectal Cancer, MSI High Colorectal Cancer.
What interventions are being tested in trial NCT03104439?
The interventions under investigation include: Nivolumab (DRUG), Ipilimumab (DRUG), Radiation Therapy (RADIATION).
Who is sponsoring clinical trial NCT03104439?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03104439 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pancreatic Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
NC410 and FOLFIRINOX in Combination With Nivolumab With or Without Ipilimumab in Patients With Untreated Metastatic Pancreatic Cancer
RECRUITING · Phase 2
-
Pancreatic Cancer Adaptive Neoadjuvant Chemotherapy Trial
RECRUITING · Phase 2
-
Modulation of the Gut Microbiome With Pembrolizumab Following Chemotherapy in Resectable Pancreatic Cancer
RECRUITING · Phase 2
-
Study of Amplitude-Modulated Radiofrequency Electromagnetic Fields in Metastatic Pancreatic Cancer
RECRUITING · Phase 2
-
PurIST Classification-Guided Adaptive Neoadjuvant Chemotherapy by RNA Expression Profiling of EUS Aspiration Samples
RECRUITING · Phase 2
-
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers
RECRUITING · Phase 2
Explore more on PlainTrial
Pancreatic Cancer
All registered trials for this condition
Microsatellite Stable Colorectal Cancer
All registered trials for this condition
Massachusetts
All trials with a study site in Massachusetts
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.